Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

Si Sun,1 Lichen Tang,2 Jian Zhang,1 Fangfang Lv,1 Zhonghua Wang,1 Leiping Wang,1 Qunling Zhang,1 Chunlei Zheng,1 Lixin Qiu,1 Zhen Jia,1 Yunhua Lu,1 Guangyu Liu,2 Zhimin Shao,2 Biyun Wang,1 Xichun Hu1 1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, S...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sun S, Tang L, Zhang J, Lv F, Wang Z, Wang L, Zhang Q, Zheng C, Qiu L, Jia Z, Lu Y, Liu G, Shao Z, Wang B, Hu X
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/521a9511dfc94c98bf008162cbfd9049
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:521a9511dfc94c98bf008162cbfd9049
record_format	dspace
spelling	oai:doaj.org-article:521a9511dfc94c98bf008162cbfd90492021-12-02T02:41:38ZCisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer1178-2013https://doaj.org/article/521a9511dfc94c98bf008162cbfd90492014-03-01T00:00:00Zhttp://www.dovepress.com/cisplatin-improves-antitumor-activity-of-weekly-nab-paclitaxel-in-pati-a16165https://doaj.org/toc/1178-2013 Si Sun,1 Lichen Tang,2 Jian Zhang,1 Fangfang Lv,1 Zhonghua Wang,1 Leiping Wang,1 Qunling Zhang,1 Chunlei Zheng,1 Lixin Qiu,1 Zhen Jia,1 Yunhua Lu,1 Guangyu Liu,2 Zhimin Shao,2 Biyun Wang,1 Xichun Hu1 1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China, 2Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China Abstract: Although nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is approved to be given every 3 weeks, weekly use of this drug is becoming a new standard of care in patients with metastatic breast cancer (MBC). This prospective Phase II study was conducted to improve the efficacy of weekly nab-paclitaxel with cisplatin in MBC patients. Seventy-three women with recurrent or MBC were eligible for participation. Nab-paclitaxel was administered weekly at a dose of 125 mg/m2 on day 1, day 8, and day 15, followed by cisplatin 75 mg/m2 on day 1, repeated every 28 days with a maximum of 6 cycles. The primary objective was investigator-assessed overall response rate (ORR). A high ORR of 67.1% was obtained, with rates of 80.6% for the first-line patients and 80% for patients not pretreated with taxanes. Among those who had objective responses, a large percentage of patients (83.7%) showed quickly remarkable tumor shrinkage during the first two cycles. The median progression-free and overall survival times were 9.8 and 26.9 months, respectively. For the patients receiving first-, second-, and third-line therapy or beyond, median progression-free survival was 11.7, 7.7, and 7.6 months, respectively (P=0.005). Molecular subtype was not significantly associated with ORR or disease progression. Grade 4 neutropenia occurred in 46 patients (63.0%), with febrile neutropenia found in 9 patients (12.3%). Grade 3 peripheral neuropathy was an accumulated dose-limiting toxicity occurring in 19 patients (26.0%). Efficacy of weekly nab-paclitaxel can be improved by adding cisplatin. The doublet is highly effective, with quick response, manageable toxicity, and possible equivalence across molecular subtypes in MBC patients. Keywords: metastatic breast cancer, nanoparticle albumin-bound paclitaxel, cisplatin, taxane-pretreatedSun STang LZhang JLv FWang ZWang LZhang QZheng CQiu LJia ZLu YLiu GShao ZWang BHu XDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 1443-1452 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Sun S Tang L Zhang J Lv F Wang Z Wang L Zhang Q Zheng C Qiu L Jia Z Lu Y Liu G Shao Z Wang B Hu X Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
description	Si Sun,1 Lichen Tang,2 Jian Zhang,1 Fangfang Lv,1 Zhonghua Wang,1 Leiping Wang,1 Qunling Zhang,1 Chunlei Zheng,1 Lixin Qiu,1 Zhen Jia,1 Yunhua Lu,1 Guangyu Liu,2 Zhimin Shao,2 Biyun Wang,1 Xichun Hu1 1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China, 2Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China Abstract: Although nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is approved to be given every 3 weeks, weekly use of this drug is becoming a new standard of care in patients with metastatic breast cancer (MBC). This prospective Phase II study was conducted to improve the efficacy of weekly nab-paclitaxel with cisplatin in MBC patients. Seventy-three women with recurrent or MBC were eligible for participation. Nab-paclitaxel was administered weekly at a dose of 125 mg/m2 on day 1, day 8, and day 15, followed by cisplatin 75 mg/m2 on day 1, repeated every 28 days with a maximum of 6 cycles. The primary objective was investigator-assessed overall response rate (ORR). A high ORR of 67.1% was obtained, with rates of 80.6% for the first-line patients and 80% for patients not pretreated with taxanes. Among those who had objective responses, a large percentage of patients (83.7%) showed quickly remarkable tumor shrinkage during the first two cycles. The median progression-free and overall survival times were 9.8 and 26.9 months, respectively. For the patients receiving first-, second-, and third-line therapy or beyond, median progression-free survival was 11.7, 7.7, and 7.6 months, respectively (P=0.005). Molecular subtype was not significantly associated with ORR or disease progression. Grade 4 neutropenia occurred in 46 patients (63.0%), with febrile neutropenia found in 9 patients (12.3%). Grade 3 peripheral neuropathy was an accumulated dose-limiting toxicity occurring in 19 patients (26.0%). Efficacy of weekly nab-paclitaxel can be improved by adding cisplatin. The doublet is highly effective, with quick response, manageable toxicity, and possible equivalence across molecular subtypes in MBC patients. Keywords: metastatic breast cancer, nanoparticle albumin-bound paclitaxel, cisplatin, taxane-pretreated
format	article
author	Sun S Tang L Zhang J Lv F Wang Z Wang L Zhang Q Zheng C Qiu L Jia Z Lu Y Liu G Shao Z Wang B Hu X
author_facet	Sun S Tang L Zhang J Lv F Wang Z Wang L Zhang Q Zheng C Qiu L Jia Z Lu Y Liu G Shao Z Wang B Hu X
author_sort	Sun S
title	Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
title_short	Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
title_full	Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
title_fullStr	Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
title_full_unstemmed	Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
title_sort	cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/521a9511dfc94c98bf008162cbfd9049
work_keys_str_mv	AT suns cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT tangl cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT zhangj cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT lvf cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT wangz cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT wangl cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT zhangq cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT zhengc cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT qiul cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT jiaz cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT luy cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT liug cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT shaoz cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT wangb cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer AT hux cisplatinimprovesantitumoractivityofweeklynabpaclitaxelinpatientswithmetastaticbreastcancer
_version_	1718402284274057216

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

Ejemplares similares